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Introduction
Atrophic changes have been proposed
as biomarkers for differential diagnosis of
Alzheimer’s disease (AD) and amnestic
mild cognitive impairment (MCI), and
different atrophic rates have been
observed in AD, MCI-to-AD converters
(cMRI), stable MCI (sMCI), and normal
healthy controls[1]. Measurement of
atrophic changes, however, requires
longitudinal MRI studies. The purpose of
this study was to investigate the following
questions: 1. Is it possible to use
baseline volumetric MRI to predict MCI
conversion to AD, i.e., to tell if a MCI
patient is a cMCI or a sMCI? 2. What are
the predictive values of APOE genotype,
and clinical cognitive test scores?

Methods
High resolution 3D T1-weighted MPRAGE datasets at baseline and 24month of 6 AD (4 female, 2 male,
75.1+/-1.7 yrs), 11 stable MCI (sMCI, 5
female, 6 male, 75.8 +/-1.7 yrs), 9 MCI
converters (cMCI, 5 female, 4 male,
74.4 +/-1.9 yrs), 9 normal controls (5
female, 4 male, 75.3+/-1.7 yrs), and
their APOE genotypes, as well as
clinical cognitive test scores were
obtained from the ADNI database. The
3D T1WI datasets were first analyzed
using a robust automatic voxel-based
morphometry (VBM) technique which
combines a fully automated spatial
normalization
approach,
dubbed
HAMMER
(Hierarchical
Attribute
Matching Mechanism for Elastic
Registration) [2], in conjunction with a
tissue mass preserving framework
called RAVENS (Regional Analysis of
Volumes Examined in Normalized
Space) [3]. Four consecutive steps
were carried out: removal of non-brain
voxels, tissue segmentation, spatial
normalization
to
a
standardized
template, and generation of a masspreserving tissue density map (i.e.
RAVENS map) for each tissue type
(GM, WM,ventricles.
Measurements of volumes of
individual brain structures: From the
RAVENS maps of each individual
subject’s brain, the HAMMER technique
generated measurement of the sizes of
93 brain structures. These 93 structures
were labeled in the template brain. The
tissue mass preserving mechanism in

RAVENS allows for linearly translating the
average density of each labeled structure
in the RAVENS map into a measure of the
size of that specific structure in the
individual subject’s brain. The RAVENS
maps are the results of elastic registration
of original brain regions to the standard
template while preserving the original
tissue volumes.
Group
comparison
to
identify
structures that are different between
groups in comparison: Unpaired t-test
was carried out to identify structures that
are significantly different among groups in
comparison.
Data-driven statistical analysis: In each
group of subjects in comparison (i.e.,
normal, AD, sMCI, or cMRI), subjects were
put into “model” or “test” group.
Histograms of each brain structure of
interest of the model data were generated,
and a threshold of structural volume or
atrophy rate was defined that gave the
highest diagnostic accuracy for the model
data. Then the volume or atrophy rate of
the structure in each “test” subject was
compared to the threshold to diagnose the
subject. The diagnoses were compared
with the known disease status of the test
subjects to assess the diagnostic accuracy
of using a specific structure for diagnosis
purpose.
Flow-chart of the image
processing using the HAMMER
technique and RAVENS

Quality control of the use of HAMMER
and RAVENS: In an effort to validate the
HAMMER and RAVENS methodology, two
researchers in our lab independently
performed manual segmentation of the
lateral ventricles in one normal adolescent
subject and compared the manual results
with that obtained with the HAMMER
technique. The following table demonstrated
good agreement between the manual results
and that obtained with the HAMMER
technique:
Left Ventricle
(mm3)

Right Ventricle
(mm3)

Rater 1

7,676

13,002

Rater 2

7,314

13,466

7,760 (3.5%
difference)

12,924 (2.3%
difference)
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middle temporal gyrus) showed distinctively
different baseline volumes as compared with
the stable MCI group, indicating that the
baseline volumetric measurement of these
structures may have predictive prognosis
value for identifying MCI converters.
Analysis of the diagnostic accuracy of these
structures’ baseline volumes, along with that
of APOE genotype, and clinical cognitive
test scores showed ~88% diagnostic
accuracy (cMCI vs sMCI) using these
structures’ baseline volumes, while APOE
genotype, and clinical cognitive test scores
have much lower diagnostic accuracy for
differentiating cMCI vs sMCI (<70%). MM
Score, however, provides fairly high
diagnostic accuracy for differentiating
normal vs sMCI (88%), normal vs cMCI
(77%), normal vs AD (90%), and sMCI vs
AD (85%).

We further carried out a test-retest study by
analyzing data from 5 normal subjects
scanned twice within 3 months. Comparing
the HAMMER-measured sizes of the 93
structures between the two scans three
months apart in the 5 subjects lead to a
mean coefficient of variation of 12±6,
suggesting good test-retest reliability of the
volumes of the brain structures measured by
the HAMMER & RAVENS techniques.

This study has reinforced the value of MRI
as a potential surrogate marker of AD and
MCI. Importantly, this study provided
evidence that it is possible to use baseline
volumetric MRI to predict a MCI patient to
be a converter or a stable MCI.

Results
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